The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage.
Recombinant activated factor VII (rFVIIa) was originally developed for the treatment of bleeding in patients with haemophilia A or B and inhibitors. Over the past ten years, it has been successfully used to prevent or control bleeding in several other nonhaemophilic bleeding conditions. Among the newer 'off-label' clinical applications of rFVIIa, there is increasing evidence of its effectiveness in treating obstetric and gynaecological bleeding unresponsive to conventional therapy. The existing literature on the use of rFVIIa in obstetrics and gynaecology is summarised in this review. Although supported by few and uncontrolled studies, on the whole, the published data suggest a potential role of rFVIIa in the management of obstetric and gynaecological intractable bleeding. However, further evidence is needed to improve the assessment of its optimal dose, effectiveness and safety in such conditions.
Franchini
M
M
Servizio di Immunoematologia e Trasfusione-Centro Emofilia, Ospedale Policlinico Azienda Ospedaliera di Verona, Verona, Italy. massimo.franchini@azosp.vr.it
Lippi
G
G
Franchi
M
M
D000328:Adult; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D006473:Postpartum Hemorrhage / Q000517:prevention & control*; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D015942:Factor VIIa